Description

History / Background

MOTS-C (Mitochondrial Open Reading Frame of 12S rRNA type-C) is a mitochondrial-derived peptide discovered in 2016. It is encoded by mitochondrial DNA and belongs to a class of peptides that influence metabolic processes.

Initial research focused on metabolic regulation, particularly regarding obesity, insulin resistance, and age-related metabolic conditions. Subsequent studies have explored its potential effects on health span, lifespan, and overall cellular energy metabolism.

Research For

Potential benefits of MOTS-C include:

1. Metabolic Regulation
   Improves insulin sensitivity and glucose metabolism, which may benefit individuals with metabolic disorders such as type 2 diabetes.

2. Weight Management
   May aid in weight loss and reduce fat accumulation, making it a candidate for obesity-related interventions.

3. Anti-Aging Effects
   Supports mitochondrial function and promotes healthy aging by enhancing cellular energy metabolism.

4. Exercise Performance
   May enhance physical performance and exercise capacity, potentially benefiting athletes and active individuals.

Important Considerations

• Regulatory Status: MOTS-C is not approved by the FDA or other regulatory bodies for clinical use. Its use outside controlled research settings should be approached with caution.

• Side Effects: Safety data is limited; potential side effects and long-term safety remain under investigation.

• Individual Variability: Responses may vary based on age, sex, and overall health.

• Healthcare Consultation: Essential for any therapeutic consideration due to experimental status and lack of established long-term data.